Treatment Option Overview
The treatment of patients with acquired immunodeficiency syndrome
(AIDS)-related lymphomas presents the challenge of integrating therapy
appropriate for the stage and histologic subset of malignant lymphoma with the
limitations imposed by HIV infection, which to date is a chronic incurable illness.[1] In
addition to antitumor therapy, essential components of an optimal non-Hodgkin
lymphoma treatment strategy include highly active antiretroviral therapy, prophylaxis for
opportunistic infections, and rapid recognition and treatment of intercurrent
infections.[2] Patients with HIV positivity and underlying immunodeficiency
have poor bone marrow reserve, which compromises the potential for drug dose
intensity. Intercurrent opportunistic infection is a risk that may
also lead to a decrease in drug delivery. Furthermore, chemotherapy itself
compromises the immune system and increases the likelihood of opportunistic
infection.
References
-
Levine AM: Acquired immunodeficiency syndrome-related lymphoma: clinical aspects. Semin Oncol 27 (4): 442-53, 2000.
[PUBMED Abstract]
-
Tirelli U, Bernardi D: Impact of HAART on the clinical management of AIDS-related cancers. Eur J Cancer 37 (10): 1320-4, 2001.
[PUBMED Abstract]
Back to Top
< Previous Section | Next Section > |